Lilliam Ambroggio
Concepts (311)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community-Acquired Infections | 46 | 2026 | 179 | 12.880 |
Why?
| | Pneumonia | 47 | 2026 | 635 | 11.500 |
Why?
| | Anti-Bacterial Agents | 29 | 2026 | 1942 | 4.410 |
Why?
| | Emergency Service, Hospital | 31 | 2026 | 2363 | 3.070 |
Why?
| | Pneumonia, Bacterial | 10 | 2025 | 114 | 2.690 |
Why?
| | Respiratory Tract Infections | 14 | 2026 | 403 | 2.320 |
Why?
| | Child | 107 | 2026 | 22693 | 2.200 |
Why?
| | Infant | 61 | 2026 | 10114 | 1.800 |
Why?
| | Child, Preschool | 62 | 2026 | 11913 | 1.720 |
Why?
| | Severity of Illness Index | 14 | 2025 | 2921 | 1.660 |
Why?
| | Hospitalization | 24 | 2026 | 2475 | 1.460 |
Why?
| | Guideline Adherence | 5 | 2023 | 594 | 1.460 |
Why?
| | Macrolides | 4 | 2021 | 68 | 1.390 |
Why?
| | Pneumonia, Mycoplasma | 5 | 2025 | 56 | 1.370 |
Why?
| | Ultrasonography | 3 | 2024 | 788 | 1.360 |
Why?
| | Wounds, Gunshot | 3 | 2026 | 262 | 1.350 |
Why?
| | Length of Stay | 11 | 2025 | 1358 | 1.310 |
Why?
| | Hospitals, Pediatric | 13 | 2025 | 561 | 1.270 |
Why?
| | beta-Lactams | 3 | 2015 | 34 | 1.250 |
Why?
| | Quality Improvement | 8 | 2025 | 1354 | 1.240 |
Why?
| | Pneumonia, Pneumococcal | 2 | 2025 | 48 | 1.210 |
Why?
| | Asthma | 7 | 2026 | 1800 | 1.120 |
Why?
| | Streptococcus pneumoniae | 3 | 2025 | 187 | 1.120 |
Why?
| | Firearms | 3 | 2026 | 444 | 1.100 |
Why?
| | Propensity Score | 5 | 2025 | 376 | 1.030 |
Why?
| | Humans | 122 | 2026 | 146342 | 1.020 |
Why?
| | Prospective Studies | 35 | 2026 | 8123 | 1.010 |
Why?
| | Biomedical Research | 4 | 2023 | 729 | 1.010 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1591 | 0.980 |
Why?
| | Adolescent | 51 | 2026 | 22557 | 0.970 |
Why?
| | Bacteremia | 4 | 2019 | 218 | 0.970 |
Why?
| | Suicide | 4 | 2026 | 647 | 0.950 |
Why?
| | Retrospective Studies | 34 | 2026 | 17438 | 0.940 |
Why?
| | Male | 68 | 2026 | 73396 | 0.850 |
Why?
| | Antigens, Bacterial | 1 | 2025 | 125 | 0.840 |
Why?
| | Patient Readmission | 6 | 2026 | 778 | 0.820 |
Why?
| | Catheterization, Peripheral | 1 | 2025 | 116 | 0.810 |
Why?
| | Credentialing | 1 | 2024 | 21 | 0.810 |
Why?
| | Administration, Oral | 6 | 2026 | 872 | 0.790 |
Why?
| | Female | 69 | 2026 | 79499 | 0.790 |
Why?
| | Outpatients | 4 | 2024 | 440 | 0.780 |
Why?
| | Ambulatory Care | 6 | 2026 | 628 | 0.770 |
Why?
| | Mycoplasma pneumoniae | 7 | 2025 | 54 | 0.760 |
Why?
| | Thiamine Deficiency | 1 | 2022 | 9 | 0.720 |
Why?
| | Radiography, Thoracic | 4 | 2022 | 174 | 0.720 |
Why?
| | Point-of-Care Systems | 1 | 2024 | 185 | 0.700 |
Why?
| | Communicable Diseases | 1 | 2023 | 166 | 0.670 |
Why?
| | Evidence-Based Medicine | 2 | 2015 | 731 | 0.670 |
Why?
| | Mass Screening | 4 | 2026 | 1307 | 0.630 |
Why?
| | Mental Health Services | 1 | 2025 | 450 | 0.620 |
Why?
| | Administration, Intravenous | 3 | 2025 | 172 | 0.610 |
Why?
| | Microbiota | 5 | 2026 | 725 | 0.580 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 253 | 0.550 |
Why?
| | Patient Discharge | 3 | 2022 | 997 | 0.550 |
Why?
| | Adrenal Cortex Hormones | 4 | 2023 | 486 | 0.540 |
Why?
| | Pneumonia, Necrotizing | 1 | 2017 | 1 | 0.520 |
Why?
| | Sepsis | 3 | 2022 | 669 | 0.520 |
Why?
| | Drug Prescriptions | 3 | 2020 | 314 | 0.510 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2023 | 83 | 0.510 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2017 | 26 | 0.500 |
Why?
| | Pediatrics | 4 | 2024 | 1124 | 0.480 |
Why?
| | Viruses | 3 | 2023 | 165 | 0.470 |
Why?
| | Research Design | 4 | 2021 | 1143 | 0.460 |
Why?
| | Alcoholism | 1 | 2022 | 830 | 0.440 |
Why?
| | Biomarkers | 11 | 2025 | 4340 | 0.440 |
Why?
| | Child, Hospitalized | 4 | 2024 | 52 | 0.410 |
Why?
| | Multiplex Polymerase Chain Reaction | 3 | 2025 | 56 | 0.400 |
Why?
| | Treatment Failure | 3 | 2024 | 361 | 0.390 |
Why?
| | Research | 2 | 2016 | 421 | 0.390 |
Why?
| | ROC Curve | 4 | 2025 | 617 | 0.390 |
Why?
| | Clinical Decision-Making | 4 | 2022 | 365 | 0.380 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2025 | 58 | 0.360 |
Why?
| | Adrenomedullin | 2 | 2021 | 5 | 0.350 |
Why?
| | Virus Diseases | 2 | 2024 | 219 | 0.340 |
Why?
| | Physical Examination | 2 | 2026 | 237 | 0.330 |
Why?
| | Metabolomics | 3 | 2025 | 738 | 0.320 |
Why?
| | Fever | 3 | 2022 | 322 | 0.310 |
Why?
| | Respiratory Sounds | 3 | 2022 | 102 | 0.310 |
Why?
| | Odds Ratio | 3 | 2022 | 1077 | 0.300 |
Why?
| | Hospital Charges | 1 | 2009 | 45 | 0.300 |
Why?
| | Prognosis | 7 | 2023 | 4351 | 0.300 |
Why?
| | Simplexvirus | 1 | 2009 | 81 | 0.290 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2025 | 627 | 0.290 |
Why?
| | United States | 12 | 2024 | 16136 | 0.290 |
Why?
| | Treatment Outcome | 9 | 2026 | 11821 | 0.280 |
Why?
| | Herpes Simplex | 1 | 2009 | 103 | 0.280 |
Why?
| | Critical Illness | 6 | 2025 | 908 | 0.280 |
Why?
| | Pandemics | 4 | 2024 | 1707 | 0.270 |
Why?
| | Health Resources | 1 | 2009 | 131 | 0.270 |
Why?
| | Suicidal Ideation | 2 | 2025 | 543 | 0.270 |
Why?
| | Cohort Studies | 12 | 2025 | 6077 | 0.270 |
Why?
| | Bacteria | 5 | 2026 | 766 | 0.260 |
Why?
| | Risk Factors | 11 | 2026 | 10921 | 0.260 |
Why?
| | Feces | 2 | 2021 | 496 | 0.250 |
Why?
| | Utilization Review | 2 | 2018 | 39 | 0.250 |
Why?
| | Drug Therapy, Combination | 3 | 2015 | 1036 | 0.250 |
Why?
| | Case-Control Studies | 6 | 2025 | 3647 | 0.250 |
Why?
| | Albuterol | 1 | 2026 | 76 | 0.230 |
Why?
| | Practice Patterns, Physicians' | 4 | 2025 | 1408 | 0.230 |
Why?
| | Penicillins | 2 | 2023 | 65 | 0.230 |
Why?
| | Ohio | 2 | 2016 | 136 | 0.230 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 368 | 0.220 |
Why?
| | Positive-Pressure Respiration | 1 | 2026 | 115 | 0.220 |
Why?
| | Serogroup | 1 | 2025 | 46 | 0.220 |
Why?
| | Carrier State | 1 | 2026 | 80 | 0.220 |
Why?
| | Caregivers | 2 | 2026 | 1080 | 0.220 |
Why?
| | Bronchodilator Agents | 1 | 2026 | 186 | 0.220 |
Why?
| | Amoxicillin | 1 | 2025 | 35 | 0.220 |
Why?
| | Inpatients | 2 | 2021 | 540 | 0.220 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1763 | 0.220 |
Why?
| | Fluid Therapy | 1 | 2026 | 154 | 0.210 |
Why?
| | Influenza, Human | 2 | 2023 | 640 | 0.210 |
Why?
| | Bacteriological Techniques | 1 | 2025 | 66 | 0.210 |
Why?
| | Nasal Mucosa | 1 | 2025 | 112 | 0.210 |
Why?
| | Interrupted Time Series Analysis | 1 | 2024 | 73 | 0.210 |
Why?
| | Critical Pathways | 1 | 2025 | 104 | 0.210 |
Why?
| | Protein Precursors | 2 | 2021 | 127 | 0.200 |
Why?
| | Asymptomatic Infections | 1 | 2024 | 40 | 0.200 |
Why?
| | Trachea | 1 | 2026 | 253 | 0.200 |
Why?
| | Infant, Newborn | 7 | 2025 | 6460 | 0.200 |
Why?
| | Shock, Septic | 1 | 2026 | 230 | 0.200 |
Why?
| | Intensive Care Units, Pediatric | 3 | 2025 | 293 | 0.200 |
Why?
| | Diagnostic Errors | 1 | 2025 | 178 | 0.200 |
Why?
| | Logistic Models | 4 | 2021 | 2126 | 0.190 |
Why?
| | Nervous System Diseases | 2 | 2016 | 288 | 0.190 |
Why?
| | Health Education | 1 | 2026 | 346 | 0.180 |
Why?
| | Family Characteristics | 1 | 2024 | 203 | 0.180 |
Why?
| | Pennsylvania | 2 | 2015 | 136 | 0.180 |
Why?
| | Pneumonia, Aspiration | 2 | 2019 | 16 | 0.180 |
Why?
| | Coinfection | 1 | 2024 | 143 | 0.180 |
Why?
| | Thiamine | 1 | 2022 | 19 | 0.180 |
Why?
| | Delphi Technique | 1 | 2024 | 350 | 0.180 |
Why?
| | Consensus | 1 | 2024 | 467 | 0.180 |
Why?
| | Follow-Up Studies | 4 | 2022 | 5439 | 0.170 |
Why?
| | Suicide, Attempted | 1 | 2025 | 391 | 0.170 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2023 | 141 | 0.170 |
Why?
| | Pleural Effusion | 1 | 2022 | 59 | 0.170 |
Why?
| | Heart Defects, Congenital | 1 | 2009 | 923 | 0.170 |
Why?
| | Nucleic Acids | 1 | 2022 | 78 | 0.160 |
Why?
| | Safety | 1 | 2023 | 347 | 0.160 |
Why?
| | Arthritis, Infectious | 1 | 2022 | 77 | 0.160 |
Why?
| | Blood Culture | 2 | 2019 | 27 | 0.160 |
Why?
| | Pediatric Emergency Medicine | 1 | 2021 | 23 | 0.160 |
Why?
| | Cross-Sectional Studies | 7 | 2026 | 5899 | 0.160 |
Why?
| | Aftercare | 1 | 2022 | 225 | 0.160 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 227 | 0.160 |
Why?
| | Quality of Life | 2 | 2023 | 3200 | 0.160 |
Why?
| | Gastroenteritis | 1 | 2021 | 63 | 0.160 |
Why?
| | Pseudomonas Infections | 1 | 2022 | 229 | 0.160 |
Why?
| | International Cooperation | 1 | 2021 | 193 | 0.150 |
Why?
| | Cytomegalovirus Vaccines | 1 | 2019 | 5 | 0.150 |
Why?
| | Osteomyelitis | 1 | 2022 | 148 | 0.150 |
Why?
| | Proteome | 1 | 2024 | 520 | 0.150 |
Why?
| | State Medicine | 1 | 2019 | 23 | 0.150 |
Why?
| | Societies | 1 | 2019 | 40 | 0.150 |
Why?
| | Clinical Deterioration | 1 | 2019 | 10 | 0.150 |
Why?
| | Intensive Care Units | 3 | 2021 | 925 | 0.150 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 74 | 0.140 |
Why?
| | Public Health | 1 | 2024 | 574 | 0.140 |
Why?
| | Physicians | 2 | 2021 | 955 | 0.140 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2018 | 20 | 0.140 |
Why?
| | Central Nervous System Diseases | 1 | 2019 | 73 | 0.140 |
Why?
| | Diarrhea | 1 | 2020 | 190 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2026 | 733 | 0.140 |
Why?
| | Prednisolone | 2 | 2020 | 65 | 0.140 |
Why?
| | Cytomegalovirus | 1 | 2019 | 172 | 0.140 |
Why?
| | Infectious Disease Medicine | 1 | 2018 | 12 | 0.140 |
Why?
| | Influenza B virus | 1 | 2018 | 47 | 0.140 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2018 | 50 | 0.130 |
Why?
| | Anti-Asthmatic Agents | 1 | 2020 | 263 | 0.130 |
Why?
| | Reproducibility of Results | 4 | 2026 | 3416 | 0.130 |
Why?
| | Observer Variation | 2 | 2016 | 356 | 0.130 |
Why?
| | Prednisone | 2 | 2020 | 229 | 0.130 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 298 | 0.130 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 220 | 0.130 |
Why?
| | Proteomics | 1 | 2024 | 1203 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 206 | 0.130 |
Why?
| | Pilot Projects | 1 | 2023 | 1888 | 0.130 |
Why?
| | Cytokines | 1 | 2025 | 2081 | 0.130 |
Why?
| | Immunization Schedule | 1 | 2018 | 187 | 0.120 |
Why?
| | Antibody Formation | 1 | 2018 | 290 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6073 | 0.120 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2018 | 162 | 0.120 |
Why?
| | Fatal Outcome | 1 | 2017 | 302 | 0.120 |
Why?
| | Dexamethasone | 2 | 2020 | 368 | 0.120 |
Why?
| | Models, Statistical | 1 | 2020 | 669 | 0.120 |
Why?
| | Intersectoral Collaboration | 1 | 2016 | 64 | 0.120 |
Why?
| | Killer Cells, Natural | 1 | 2019 | 481 | 0.120 |
Why?
| | Mental Disorders | 1 | 2025 | 1148 | 0.120 |
Why?
| | Patient Transfer | 1 | 2019 | 224 | 0.120 |
Why?
| | Health Services Research | 1 | 2018 | 390 | 0.120 |
Why?
| | Anaphylaxis | 1 | 2017 | 105 | 0.110 |
Why?
| | Efficiency, Organizational | 1 | 2016 | 144 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 332 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 2 | 2017 | 367 | 0.110 |
Why?
| | Emergency Medicine | 1 | 2018 | 280 | 0.110 |
Why?
| | Hospitalists | 1 | 2019 | 288 | 0.110 |
Why?
| | Azithromycin | 2 | 2025 | 101 | 0.100 |
Why?
| | Inservice Training | 1 | 2015 | 115 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1543 | 0.100 |
Why?
| | Risk Assessment | 4 | 2026 | 3712 | 0.100 |
Why?
| | Hypoxia | 2 | 2024 | 1211 | 0.100 |
Why?
| | Societies, Medical | 1 | 2018 | 907 | 0.100 |
Why?
| | Influenza Vaccines | 1 | 2018 | 544 | 0.100 |
Why?
| | Palliative Care | 1 | 2021 | 1032 | 0.090 |
Why?
| | Precision Medicine | 1 | 2017 | 462 | 0.090 |
Why?
| | Ethics, Research | 1 | 2012 | 33 | 0.090 |
Why?
| | Binomial Distribution | 1 | 2012 | 8 | 0.090 |
Why?
| | Nasopharynx | 2 | 2023 | 72 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 1998 | 0.090 |
Why?
| | Age Factors | 2 | 2022 | 3347 | 0.090 |
Why?
| | Linear Models | 1 | 2015 | 857 | 0.090 |
Why?
| | Penicillin Resistance | 1 | 2012 | 9 | 0.090 |
Why?
| | Cystic Fibrosis | 1 | 2022 | 1164 | 0.090 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 196 | 0.090 |
Why?
| | Medical Informatics | 1 | 2012 | 102 | 0.090 |
Why?
| | Academic Medical Centers | 1 | 2015 | 561 | 0.090 |
Why?
| | Drug Therapy | 1 | 2012 | 85 | 0.090 |
Why?
| | Vulnerable Populations | 1 | 2012 | 178 | 0.080 |
Why?
| | Metagenomics | 2 | 2023 | 154 | 0.080 |
Why?
| | Comparative Effectiveness Research | 1 | 2012 | 171 | 0.080 |
Why?
| | Plasma | 1 | 2012 | 222 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 2 | 2024 | 2786 | 0.080 |
Why?
| | C-Reactive Protein | 2 | 2025 | 429 | 0.080 |
Why?
| | Information Systems | 1 | 2009 | 58 | 0.070 |
Why?
| | Acyclovir | 1 | 2009 | 97 | 0.070 |
Why?
| | Health Care Costs | 1 | 2012 | 423 | 0.070 |
Why?
| | Patient Safety | 1 | 2012 | 352 | 0.070 |
Why?
| | Overweight | 1 | 2012 | 614 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1064 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2025 | 1503 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 846 | 0.060 |
Why?
| | Respiration, Artificial | 2 | 2023 | 711 | 0.060 |
Why?
| | Databases, Factual | 1 | 2012 | 1493 | 0.060 |
Why?
| | Time Factors | 3 | 2024 | 7109 | 0.060 |
Why?
| | Isotonic Solutions | 1 | 2026 | 43 | 0.060 |
Why?
| | Lung | 3 | 2024 | 4122 | 0.060 |
Why?
| | Renal Replacement Therapy | 1 | 2026 | 102 | 0.060 |
Why?
| | Chemokine CXCL10 | 1 | 2025 | 39 | 0.050 |
Why?
| | Video Recording | 1 | 2026 | 219 | 0.050 |
Why?
| | Hospital Mortality | 2 | 2020 | 1051 | 0.050 |
Why?
| | Respiratory Rate | 1 | 2024 | 24 | 0.050 |
Why?
| | Arkansas | 1 | 2024 | 23 | 0.050 |
Why?
| | Clinical Competence | 1 | 2012 | 1272 | 0.050 |
Why?
| | Creatinine | 1 | 2026 | 511 | 0.050 |
Why?
| | Adult | 6 | 2026 | 41087 | 0.050 |
Why?
| | Drug Resistance, Microbial | 1 | 2024 | 67 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2009 | 779 | 0.050 |
Why?
| | Uncertainty | 1 | 2024 | 145 | 0.050 |
Why?
| | Young Adult | 4 | 2025 | 14330 | 0.050 |
Why?
| | Canada | 1 | 2024 | 432 | 0.050 |
Why?
| | Cotinine | 1 | 2023 | 77 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 46 | 0.050 |
Why?
| | Tachypnea | 1 | 2022 | 3 | 0.050 |
Why?
| | Viral Load | 1 | 2024 | 526 | 0.040 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 67 | 0.040 |
Why?
| | Smoke | 1 | 2023 | 149 | 0.040 |
Why?
| | Gestalt Theory | 1 | 2021 | 2 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2023 | 974 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2026 | 2070 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2024 | 561 | 0.040 |
Why?
| | Disease Outbreaks | 1 | 2024 | 422 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2026 | 1135 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 441 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2022 | 173 | 0.040 |
Why?
| | Feedback | 1 | 2021 | 183 | 0.040 |
Why?
| | Emergency Treatment | 1 | 2021 | 122 | 0.040 |
Why?
| | Calcitonin | 1 | 2020 | 26 | 0.040 |
Why?
| | Medicaid | 1 | 2024 | 477 | 0.040 |
Why?
| | Heart Rate | 1 | 2024 | 846 | 0.040 |
Why?
| | Pneumocystis Infections | 1 | 2019 | 1 | 0.040 |
Why?
| | Documentation | 1 | 2022 | 202 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 147 | 0.040 |
Why?
| | Fatigue | 1 | 2022 | 363 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2020 | 109 | 0.040 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2026 | 640 | 0.040 |
Why?
| | Regression Analysis | 1 | 2022 | 999 | 0.040 |
Why?
| | Pseudomonas aeruginosa | 1 | 2022 | 392 | 0.040 |
Why?
| | Central Venous Catheters | 1 | 2020 | 53 | 0.040 |
Why?
| | Transcriptome | 1 | 2026 | 1068 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2020 | 284 | 0.040 |
Why?
| | Acute Disease | 1 | 2022 | 1038 | 0.040 |
Why?
| | Obesity | 1 | 2012 | 3131 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 790 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2026 | 1792 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2019 | 321 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 507 | 0.040 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2018 | 39 | 0.030 |
Why?
| | Data Display | 1 | 2018 | 20 | 0.030 |
Why?
| | Acute Kidney Injury | 1 | 2026 | 866 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2018 | 218 | 0.030 |
Why?
| | Gene Expression | 1 | 2022 | 1463 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 1031 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2026 | 1408 | 0.030 |
Why?
| | Bias | 1 | 2017 | 197 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2019 | 330 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2017 | 426 | 0.030 |
Why?
| | Colorado | 1 | 2026 | 4595 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 881 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2018 | 343 | 0.030 |
Why?
| | Data Collection | 1 | 2018 | 650 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2019 | 887 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2018 | 689 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2018 | 901 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2936 | 0.020 |
Why?
| | Prevalence | 1 | 2020 | 2861 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2019 | 2012 | 0.020 |
Why?
| | Aged | 2 | 2022 | 26432 | 0.020 |
Why?
| | Primary Health Care | 1 | 2020 | 1776 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 7230 | 0.010 |
Why?
| | Registries | 1 | 2012 | 2400 | 0.010 |
Why?
|
|
Ambroggio's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|